|
|
|
| home > ebr > Spring 2018 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR Editor Dr Deborah O’Neil looks at the potential of cannabis use in healthcare, relating it to topics discussed in this edition.
|
|
|
|
Future Migraine Treatment
Getting Ahead
Recent advancements in biopharmaceuticals in the area of migraine studies have the potential to bring relief to many individuals. Professor Dr Uwe Reuter at Charité Universitätsmedizin explains how.
|
|
|
|
|
Immunogenicity and the Development of Biopharmaceuticals
Sudden Impact
Dr Gary Bembridge and Dr Karen Hills at Abzena comment on the approaches that can be taken in the pre-clinical stages to reduce the effects of immunogenicity on patient experience and product success.
|
|
|
Technologies for Targeting the Cell Surfaceome
Scratching the Surface
Dr Maria Pavlou and Dr Paul Helbling at Dualsystems Biotech suggest that developing methodologies to study the surfaceome is crucial to cellular differentiation advancement, resulting in the creation of new treatments.
|
|
|
The Potential of Bacterial Lysates
From Pharma to Beauty
Bacterial lysates can be used in many applications, especially disease protection, due to their ability to act as an immune stimulant. Dr Christian Sanchez and Maxence de Villemeur at Lallemand Pharma analyse further.
|
|
|
|
Regulatory Challenges
Rules for Success
Dr William Bridges at Regulatory Affairs Professionals Society believes that regulatory aspects can propel an organisation towards success by enforcing policies, compliance, and good practices.
|
|
|
|
In Brief
Precision Healthcare
EBR’s Industry Advisor, Emile Bellott, surveys the potential ramifications of Amazon’s recently announced healthcare services, which aims to be an affordable solution for consumers.
|
|
|
|
Q&A: Albumin in Cell Culture
Therapy at Work
EBR asked Dr Daniel Shelly at Albumedix about cell therapy, looking specifically at the use of albumin in cell culture and current treatments, as well as the challenges that have to be overcome.
|
|
|
Animal Component-Free Media Formulations
Blood-Free Matters
Dr Randall Alfano at InVitria Product Development describes the use of fetal bovine serum in the advancement of in vitro biology, but suggests that a serum-free media formulation could enhance safety and reproducibility.
|
|
|
Customised Viral Engineering
Proactive Progress
Customised viral engineering can create safe and effective adeno-associated virus gene delivery, reveal Tatjana Buchholz at PlasmidFactory, Dr Carl J Christel at Sirion Biotech, and Dr Hüseyin Besir at PROGEN Biotechnik.
|
|
|
|
|
Capturing Protein-Defining Information
Redefining Proteomics
Mass spectrometry can find the proteins that make a sample, but Dr Christian Loch at AVMBioMed highlights the extract-based functional assay technique.
|
|
|
|
|
Personalised Medicine
At a Glance
Is society ready for personalised medicines and its ethical implications? Guenther Proll at Biametrics has the answer and examines the progress of its sequencing.
|
|
|
Precision Medicine
Beyond the Genome
Dr Jason Mellad at Cambridge Epigenetix states that collaboration is key to realising the potential of epigenetic research, and successive innovations and applications can aid the industry’s understanding of this.
|
|
|
Biomarkers in Oncology
Tomorrow’s Treatments
Tarquin Edwards at Peckwater PR claims that personalising cancer care and using biomarkers and personalised medicine in oncology is being supported by Big Pharma, thus transforming cancer treatments.
|
|
|
|
|
Biobanks and Strategic Processes
Data Swap
Colin Thurston at Brooks Life Sciences recommends adopting three key biobank technology solutions to make research more stratified and effective, thereby aiding researchers.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™
San Francisco, Calif. – February 16, 2022 – Unlearn®, developer
of the Twintelligent RCT™, today announced that the company has entered
into a multi-year collaboration with Merck KGaA, Darmstadt, Germany to
accelerate late-stage clinical trials with novel trial designs that
include Digital Twins. Initially, the collaboration will focus on
advancing the regulatory approval of candidates in Merck KGaA,
Darmstadt, Germany’s immunology pipeline, with the potential to expand
into other therapeutic areas.
More info >> |
|
 |
White Papers |
 |
|
The Importance of ADCC in Assessing Clinically Relevant Differences
Sartorius Stedim BioOutsource Ltd
Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >> |
|
|
